Ceribell, a Sunnyvale, CA-based provider of a cloud-linked, portable electroencephalogram (EEG), raised $50M in equity funding.
The round was led by Ally Bridge Group.
The company intends to use the funds to support ongoing commercial expansion across emergency departments and intensive care units and continue to leverage machine learning and EEG accessibility to address other neurological conditions beyond seizure.
Led by CEO Jane Chao, Ceribell deploys a cloud-linked, portable electroencephalogram (EEG) device to assess brain waves in minutes to identify the occurrence of seizures and other conditions in emergency rooms and intensive care units. The system can be quickly and easily applied to a patient by any healthcare provider and delivers brain monitoring results within minutes. The Ceribell EEG System first received FDA 510(k) clearance in 2017 and is commercially available in the United States. The company announced receipt of Breakthrough Device Designation for its delirium indication from the United States Food and Drug Administration (FDA) earlier this month.
FinSMEs
22/09/2022